Over 14 Companies Developing 18+ TIGIT Inhibitors for Cancer Therapy
Business intelligence firm DelveInsight reports that over 14 companies are actively advancing more than 18 novel TIGIT inhibitor therapies for cancer immunotherapy.
More than 14 pharmaceutical and biotechnology companies are progressing over 18 novel TIGIT inhibitor candidates as part of ongoing cancer immunotherapy development, according to a new report by DelveInsight.
The report provides a comprehensive analysis of the TIGIT inhibitor landscape, detailing both clinical and preclinical drug candidates. It evaluates therapies based on product type, development stage, route of administration, and molecular class, also noting discontinued programs.
Key companies involved in TIGIT inhibitor development include Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, and Merck KGaA. These firms are exploring TIGIT as a target to enhance the body's immune response against cancer.
TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, functions as an immune checkpoint. Inhibiting TIGIT is being investigated as a strategy to potentially boost T-cell and natural killer cell activity against tumors.